Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.
Adenine
/ adverse effects
Adiposity
/ drug effects
Antiviral Agents
/ adverse effects
Cross-Sectional Studies
DNA, Mitochondrial
/ isolation & purification
DNA, Viral
/ isolation & purification
Drug Resistance, Viral
Drug Therapy, Combination
/ adverse effects
Female
Guanine
/ adverse effects
Hepatitis B virus
/ genetics
Hepatitis B, Chronic
/ blood
Humans
Lamivudine
/ adverse effects
Leukocytes, Mononuclear
/ cytology
Male
Middle Aged
Mitochondria
/ drug effects
Organophosphonates
/ adverse effects
RNA, Mitochondrial
/ isolation & purification
Tenofovir
/ adverse effects
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 02 2020
06 02 2020
Historique:
received:
23
08
2019
accepted:
26
12
2019
entrez:
8
2
2020
pubmed:
8
2
2020
medline:
21
11
2020
Statut:
epublish
Résumé
Our study purpose was to evaluate mitochondrial (mt)DNA and RNA in peripheral blood mononuclear cells (PBMCs) and body shape changes (BSC) in HBV-infected patients. mtDNA and mtRNA were measured in PBMCs. The presence of BSC was evaluated through a questionnaire and clinical evaluation. A total of 157 subjects were enrolled, of these 107 were HBV-infected patients, 54 receiving nucleoside analogues (NAs, Group A), 53 naive to antivirals (Group B) and 50 age-sex matched controls (Group C). All HBV-treated patients had negative HBV-DNA. Twenty (37,0%) received lamivudine + adefovir, 20 (37.0%) tenofovir, 2 (3.7%) lamivudine and 12 (22.2%) entecavir. Therapy median duration was 38 months (IQR 20-60) in NA-treated patients. Group A showed significantly higher mtDNA/nuclear (n) DNA ratio (p = 0.000008) compared to Group C and Group B (p = 0.002). Group B showed significantly higher mtDNA/nDNA ratio compared to Group C (p = 0.017). Group A and B had significantly lower mtRNA/nRNA ratio compared to Group C (p = 0.00003 and p = 0.00006, respectively). Tenofovir and entecavir showed less impact compared to lamivudine + adefovir. mtDNA/nDNA ratio positively (Rho = 0.34, p < 0.05) and mtRNA/nRNA ratio negatively (Rho = -0.34, p < 0.05) correlated with therapy duration. BSC were significantly more frequent in Group A [10/54 (18.5%)] compared to Group B [3/53 (5.6%, p = 0.04)] and Group C [0/50, (p = 0.0009)]. In conclusion, long-term NA therapy was associated both to mitochondrial toxicity and BSC, showing significant differences in mtDNA and mtRNA levels. Tenofovir and entecavir showed lower impact on alterations, compared to 1
Identifiants
pubmed: 32029790
doi: 10.1038/s41598-020-58837-3
pii: 10.1038/s41598-020-58837-3
pmc: PMC7005185
doi:
Substances chimiques
Antiviral Agents
0
DNA, Mitochondrial
0
DNA, Viral
0
Organophosphonates
0
RNA, Mitochondrial
0
Lamivudine
2T8Q726O95
entecavir
5968Y6H45M
Guanine
5Z93L87A1R
adefovir
6GQP90I798
Tenofovir
99YXE507IL
Adenine
JAC85A2161
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2014Références
Schaefer, S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J. Gastroenterol. 13, 14–21 (2007).
pubmed: 17206751
pmcid: 4065870
doi: 10.3748/wjg.v13.i1.14
Cui, X. J., Cho, Y. K. & Song, B. C. Influence of the basal core promoter and precore mutation on replication of hepatitis B virus and antiviral susceptibility of different genotypes. J. Med. Virol. 87, 601–608 (2015).
pubmed: 25612255
doi: 10.1002/jmv.24117
He, Z. et al. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. Clin. Res. Hepatol. Gastroenterol. 36, 592–597 (2012).
pubmed: 23069315
doi: 10.1016/j.clinre.2012.05.012
Tanaka, E. & Matsumoto, A. Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. Hepatol. Res. 44, 1–8 (2014).
pubmed: 23607862
doi: 10.1111/hepr.12108
Carosi, G. et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig. Liver Dis. 43, 259–265 (2011).
pubmed: 21276760
doi: 10.1016/j.dld.2010.10.014
Pattullo, V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin. Mol. Hepatol. 22, 219–237 (2016).
pubmed: 27291888
pmcid: 4946398
doi: 10.3350/cmh.2016.0024
Cohen, B. H. Pharmacologic effects on Mitochondrial function. Dev. Disabil. Res. Rev. 16, 189–199 (2010).
pubmed: 20818734
doi: 10.1002/ddrr.106
Birkus, G., Hitchcock, M. J. & Cihlar, T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46, 716–723 (2002).
pubmed: 11850253
pmcid: 127499
doi: 10.1128/AAC.46.3.716-723.2002
Zhou, L. et al. Changes in Mitochondrial Toxicity in Peripheral Blood Mononuclear Cells During Four-Year Administration of Entecavir Monotherapy in Chinese Patients with Chronic Hepatitis B. Med. Sci. Monit. 21, 2058–2063 (2015).
pubmed: 26176539
pmcid: 4515935
doi: 10.12659/MSM.892937
Kampira, E. et al. Peripheral blood mitochondrial DNA/nuclear DNA (mtDNA/nDNA) ratio as a marker of mitochondrial toxicities of stavudine containing antiretroviral therapy in HIV-infected Malawian patients. OMICS. 18, 438–445 (2014).
pubmed: 24816082
doi: 10.1089/omi.2014.0026
Montaner, J. S. et al. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 34(Suppl 1), S85–90 (2003).
pubmed: 14562863
doi: 10.1097/00126334-200309011-00013
Vidal, F. et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob. Agents Chemother. 50, 3824–3832 (2006).
pubmed: 16940060
pmcid: 1635212
doi: 10.1128/AAC.00437-06
Madeddu, G. et al. Body fat changes and mitochondrial alterations during HBV treatment: a warning for long term administration. J. Infect. 65, 467–470 (2012).
pubmed: 22796021
doi: 10.1016/j.jinf.2012.07.002
Mulligan, K. et al. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women’s Interagency HIV Study. J. Acquir Immune Defic. Syndr. 38, 18–22 (2005).
pubmed: 15608519
doi: 10.1097/00126334-200501010-00004
pmcid: 15608519
Caron, M., Auclair, M., Sterlingot, H., Kornprobst, M. & Capeau, J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS. 17, 2437–2444 (2003).
pubmed: 14600514
doi: 10.1097/00002030-200311210-00005
pmcid: 14600514
Vernochet, C. et al. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation. AIDS. 17, 2177–2180 (2003).
pubmed: 14523274
doi: 10.1097/00002030-200310170-00005
pmcid: 14523274
Smith, D. E. et al. Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study. AIDS. 16, 2489–2491 (2002).
pubmed: 12461429
doi: 10.1097/00002030-200212060-00020
Lee, H., Hanes, J. & Johnson, K. A. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry. 42, 14711–14719 (2003).
pubmed: 14674745
doi: 10.1021/bi035596s
pmcid: 14674745
Pérez-Molina, J. A., Domingo, P., Martínez, E. & Moreno, S. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J. Antimicrob. Chemother. 62, 234–245 (2008).
pubmed: 18480167
doi: 10.1093/jac/dkn191
De Socio, G. V. et al. CISAI study group. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J. Infect. 57, 33–40 (2008).
pubmed: 18436307
doi: 10.1016/j.jinf.2008.03.007
Lake, J. E. et al. Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care. 23, 929–938 (2011).
pubmed: 21767228
pmcid: 3249238
doi: 10.1080/09540121.2010.543885
Shutt, T. E. & Shadel, G. S. A compendium of human mitochondrial gene expression machinery with links to disease. Environ. Mol. Mutagen. 51, 360–379 (2010).
pubmed: 20544879
pmcid: 2886302
Birkus, G., Gibbs, C. S. & Cihlar, T. Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. J. Viral. Hepat. 10, 50–54 (2003).
pubmed: 12558912
doi: 10.1046/j.1365-2893.2003.00399.x
Lok, A. S. F. & McMahon, B. J. AASLD practice guideline: chronic hepatitis B. Hepatology. 45, 507–539 (2007).
pubmed: 17256718
doi: 10.1002/hep.21513
Martin, P. et al. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clin. Gastroenterol. Hepatol. 13, 2071–87 (2015).
pubmed: 26188135
doi: 10.1016/j.cgh.2015.07.007
Fleischer, R. D. & Lok, A. S. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis. J. Hepatol. 51, 787–791 (2009).
pubmed: 19665816
doi: 10.1016/j.jhep.2009.06.011
Chu, C. K. et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir. Ther. 3(Suppl 3), 113–121 (1998).
pubmed: 10726061
Lewis, W., Day, B. J. & Copeland, W. C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug. Discov. 2, 812–822 (2003).
pubmed: 14526384
doi: 10.1038/nrd1201
Liaw, Y. F. et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 136, 486–495 (2009).
pubmed: 19027013
doi: 10.1053/j.gastro.2008.10.026
Lampertico, P. et al. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment. Pharmacol. Ther. 44, 16–34 (2016).
pubmed: 27198929
doi: 10.1111/apt.13659
EASL Clinical Practice Guidelines:. Management of chronic hepatitis B virus infection European Association for the Study of the Liver. J. Hepatol. 67(2), 370–398 (2017).
doi: 10.1016/j.jhep.2017.03.021
Walker, U. A., Setzer, B. & Venhoff, N. Increased long-term mitochondrial toxicity in combination of nucleoside analog reverse-transcriptase inhibitors. AIDS. 16, 2165–2173 (2002).
pubmed: 12409738
doi: 10.1097/00002030-200211080-00009
Cai, Q. et al. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One. 11, e0164210 (2016).
pubmed: 27711135
pmcid: 5053414
doi: 10.1371/journal.pone.0164210
Côté, H. C. et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N. Engl. J. Med. 346, 811–820 (2002).
pubmed: 11893792
doi: 10.1056/NEJMoa012035
Miró, O. et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin. Infect. Dis. 39, 710–716 (2004).
pubmed: 15356787
doi: 10.1086/423176
Lund, K. C., Peterson, L. L. & Wallace, K. B. Absence of a Universal Mechanism of Mitochondrial Toxicity by Nucleoside Analogs. Antimicrob. Agents Chemother. 51, 2531–2539 (2007).
pubmed: 17470651
pmcid: 1913246
doi: 10.1128/AAC.00039-07
López, S. et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir. Ther. 9, 47–55 (2004).
pubmed: 15040536
pmcid: 15040536
McComsey, G., Bai, R., Maa, J. F. & Wong, L. J. Extensive Investigations of Mitochondrial DNA Genome in Lipoatrophy: Beyond mtDNA depletion. J. Acquir. Immune Defic. Syndr. 39, 181–188 (2005).
pubmed: 15905734
pmcid: 15905734
Peraire, J. et al. HIV-1 infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors. Curr. HIV Res. 5, 467–473 (2007).
pubmed: 17896966
doi: 10.2174/157016207781662452
pmcid: 17896966
Jacotot, E. et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J. Exp. Med. 191, 33–46 (2000).
pubmed: 10620603
pmcid: 2195797
doi: 10.1084/jem.191.1.33
Casula, M. et al. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1- infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. J. Infect. Dis. 192, 1794–1800 (2005).
pubmed: 16235179
doi: 10.1086/497140
Galluzzi, L. et al. Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir. Ther. 10, 191–195 (2005).
pubmed: 15751778
d’Amati, G. & Lewis, W. Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells. Lab. Invest. 71, 879–884 (1994).
pubmed: 7528833